Health Economics Outcomes evaluation of Stago D-dimer
Improved patient outcomes and experience, shorter length of stay and cost effectiveness drive the recognition of value in today’s rapidly-evolving and competitive healthcare environment.
Read more
FDA grants de novo for the HemoSonics’ Quantra System
March 13, 2019 : Stago is proud to announce that HemoSonics, a Stago Group company, has been granted de novo marketing authorization by the FDA for its revolutionary diagnostic device Quantra Hemostasis Analyzer platform, and its initial QPlus cartridge. The system is now commercially available in the USA.
Read more
Stago Webinar available on-demand!
The Stago webinars have successfully gathered colleagues from all around the world. If you have missed the live events or are interested in reviewing it, the 30-minute recorded version is now available online 24/7.
Read more
